The myelodysplastic syndromes are characterized by ineffective hematopoiesis and refractory cytopenias. In an attempt to improve hematopoiesis, we administered recombinant human granulocyte--macrophage colony-stimulating factor (GM-CSF) to eight patients with myelodysplastic syndrome, as part of a Phase I trial. The GM-CSF was given by continuous intravenous infusion daily for two weeks and then again after a two-week rest period. Over the entire dose range tested (30 to 500 micrograms per square meter of body-surface area), treatment was associated with marked increases in peripheral-blood leukocytes (5- to 70-fold), including granulocytes (5- to 373-fold), in all eight patients. The absolute number of monocytes, eosinophils, and lymphocytes increased in all patients. Three of eight patients also had 2- to 10-fold increases in platelet counts and improvement in erythropoiesis, with the result that two of three patients who had required red-cell and platelet transfusions no longer needed them (at 20 to 27 weeks of follow-up). Treatment was also associated with increased marrow cellularity and a decreased percentage of blasts in the bone marrow of patients with excess blasts, resulting in an increase in the ratio of differentiated myeloid cells to immature myeloid cells. We observed relatively few side effects, but bone pain was dose-limiting when it was associated with high white-cell counts. Our results showed that GM-CSF is a potent stimulator of hematopoiesis in vivo and may produce hematologic improvement in the short term (8 to 32 weeks of observation) in patients with myelodysplastic syndrome. More experience, with longer follow-up periods, will be necessary to assess the long-term safety and efficacy of this new treatment.
Source Information
Department of Clinical Immunology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
This article has been cited by other articles:
Shikama, Y., Shichishima, T., Matsuoka, I., Jubinsky, P. T., Sieff, C. A., Maruyama, Y.
(2005). Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common {beta} chain in neutrophils of myelodysplastic syndromes. J. Leukoc. Biol.
77: 811-819
[Abstract][Full Text]
Farese, A. M., Casey, D. B., Smith, W. G., Vigneulle, R. M., McKearn, J. P., MacVittie, T. J.
(2001). Leridistim, a Chimeric Dual G-CSF and IL-3 Receptor Agonist, Enhances Multilineage Hematopoietic Recovery in a Nonhuman Primate Model of Radiation-Induced Myelosuppression: Effect of Schedule, Dose, and Route of Administration. Stem Cells
19: 522-533
[Abstract][Full Text]
Farese, A. M., Smith, W. G., Giri, J. G., Siegel, N., McKearn, J. P., MacVittie, T. J.
(2001). Promegapoietin-1a, an Engineered Chimeric IL-3 and Mpl-L Receptor Agonist, Stimulates Hematopoietic Recovery in Conventional and Abbreviated Schedules Following Radiation-Induced Myelosuppression in Nonhuman Primates. Stem Cells
19: 329-338
[Abstract][Full Text]
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro,
(2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO
18: 3558-3585
[Full Text]
Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., Andrews, C., Venugopal, P., Gezer, S., Gregory, S., Loew, J., Robin, E., Rifkin, S., Hsu, W.-T., Huang, R.-W.
(2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood
95: 1580-1587
[Abstract][Full Text]
Thompson, J. A., Gilliland, D. G., Prchal, J. T., Bennett, J. M., Larholt, K., Nelson, R. A., Rose, E. H., Dugan, M. H., the GM/EPO MDS Study Group,
(2000). Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood
95: 1175-1179
[Abstract][Full Text]
MacVittie, T. J., Farese, A. M., Smith, W. G., Baum, C. M., Burton, E., McKearn, J. P.
(2000). Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood
95: 837-845
[Abstract][Full Text]
Heaney, M. L., Golde, D. W.
(1999). Myelodysplasia. NEJM
340: 1649-1660
[Full Text]
Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.-M., Winqvist, I., Oberg, G., Osterborg, A., Ost, A.
(1998). Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients. Blood
92: 68-75
[Abstract][Full Text]
Cheson, B. D.
(1997). The Myelodysplastic Syndromes. The Oncologist
2: 28-39
[Abstract][Full Text]
Giralt, S., Escudier, S., Kantarjian, H., Deisseroth, A., Freireich, E. J., Andersson, B. S., O'Brien, S., Andreeff, M., Fisher, H., Cork, A., Hirsch-Ginsberg, C., Trujillo, J., Stass, S., Champlin, R. E.
(1993). Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation. NEJM
329: 757-761
[Abstract][Full Text]
Lindley, C. M., Gordon, T. R.
(1991). Application of Biotechnology Products in Oncology. Journal of Pharmacy Practice
4: 117-130
(1987). NEW TREATMENT FOR MYELODYSPLASTIC SYNDROMES. JWatch General
1987: 2-2
[Full Text]
